[Acceptability of auto-injection of vasoactive drugs in the treatment of erectile dysfunction]

Arch Esp Urol. 1999 Nov;52(9):973-7.
[Article in Spanish]

Abstract

Objectives: To study the utility of the PenInject 2.25 (SHL Medical AB), an instrument for intracavernous auto-injection of vasoactive drugs.

Methods: 61 males, aged 30-70 years, with erectile dysfunction were studied. The study comprised two groups: group A consisted of 26 patients previously treated with intracavernous injections using a syringe that were started on treatment with the self-injector, and group B consisted of 35 previously untreated patients that started treatment directly with the self-injector. Different data and questions on the facility of use and acceptance of the instrument were analyzed. Data evaluation were plotted on visual analog scales of 10 cm. A score of 5 or more showed good results and less than 5 was considered unfavorable.

Results: The positive aspects were facility of use, comfort, design of the self-injector, which scored higher than 7. The negative aspects were pain, fear, discomfort intensity, which scored below 4.

Conclusions: The use of the PenInject self-injector in this group of patients improved the acceptability of intracavernous therapy for erectile dysfunction in comparison to the classical syringe.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Equipment Design
  • Humans
  • Impotence, Vasculogenic / drug therapy*
  • Injections / instrumentation
  • Male
  • Middle Aged
  • Self Administration
  • Vasodilator Agents / administration & dosage*

Substances

  • Vasodilator Agents